US FDA declines to approve Rocket Pharma's immune disorder gene therapy

Rocket Pharmaceuticals

28/06/2024 12:30

June 28 (Reuters) - The U.S. Food and Drug
Administration has declined to approve Rocket Pharmaceuticals'
 RCKT.O  gene therapy to treat a rare and severe pediatric
disorder that causes the immune system to malfunction, the
company said on Friday.    
    

 (Reporting by Pratik Jain in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Pratik.Jain@thomsonreuters.com;))